摘要
目的探究美托洛尔与曲美他嗪联合治疗冠心病心力衰竭的临床效果。方法选取2017年2月—2018年1月冠心病心力衰竭患者96例,分为实验组(采用美托洛尔与曲美他嗪联合治疗)与常规组(采用美托洛尔治疗),比较两组患者临床疗效、各项心功能指标及不良反应情况。结果实验组临床疗效(93.75%)优于常规组(81.25%),差异有统计学意义(χ~2=7.142,P<0.05);实验组患者的左心室舒张末期内经为(51.48±3.01)mm,常规组左心室舒张末期内经为(59.72±2.84)mm,左心室舒张末期内经等各项心功能指标均优于常规组,差异有统计学意义(t=13.795,P<0.05);实验组患者不良反应情况(4.16%)优于常规组(25.00%),差异有统计学意义(χ~2=17.424,P<0.05)。结论托洛尔与曲美他嗪联合治疗冠心病心力衰竭,能有效提高临床疗效。
Objective To investigate the clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease with heart failure.Methods 96 patients with coronary heart disease and heart failure from February 2017 to January 2018 were enrolled.The patients were divided into experimental group(treated with metoprolol and trimetazidine)and conventional group(treated with metoprolol).The clinical efficacy and various factors of the two groups were compared as well as the cardiac function indicators and adverse reactions.Results The clinical efficacy of the experimental group(93.75%)was better than that of the conventional group(81.25%).The difference was statistically significant(χ^2=7.142,P<0.05).The left ventricular end-diastolic period of the experimental group was(51.48±3.01)mm.In the conventional group,the left ventricular end-diastolic period was(59.72±2.84)mm,and the left ventricular end-diastolic period was better than the conventional group.The difference was statistically significant(t=13.795,P<0.05).The adverse reactions of patients(4.16%)were better than those of the conventional group(25.00%),and the difference was statistically significant(χ^2=17.424,P<0.05).Conclusion Torolol combined with trimetazidine in the treatment of coronary heart disease with heart failure can effectively improve the clinical efficacy.
作者
王为应
WANG Wei-ying(Department of Cardiology,Jiaozhou People's Hospital,Jiaozhou,Shandong Province,266000 China)
出处
《系统医学》
2019年第5期47-49,共3页
Systems Medicine
关键词
美托洛尔
曲美他嗪
冠心病心力衰竭
Metoprolol
Trimetazidine
Coronary heart disease heart failure
